MGH Cancer Center Grand Rounds 2023-2024
Description: MGH Cancer Center Grand Rounds 2023-2024 Circulating Tumor DNA Analysis for Non-Invasive Detection of Cancers May 9, 2024 12:00-1:00 PM Learning Objectives Upon completion of this activity, participants will be able to: Evaluate recent
Related Topics
Download Presentation
"MGH Cancer Center Grand Rounds 2023-2024" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. MGH Cancer Center Grand Rounds 2023-2024
Circulating Tumor DNA Analysis for Non-Invasive Detection of Cancers
May 9, 2024 | 12:00-1:00 PM Learning Objectives Upon completion of this activity, participants will be able to:
Evaluate recent advances or controversies in hematology/oncology treatment, clinical research and/or basic science investigation presented in this series
Assess opportunities to integrate information, tools or practices presented in this conference into how you deliver or support research and patient care
Incorporate new information or perspectives from this conference into specific aspects of your responsibilities in patient care, research or the system in which you work
Recognize evolving landscape of cancer care worldwide
Demonstrate the role of team science in the advancement of hematology/oncology treatment, clinical research and/or basic science investigation presented in this series
Target Audience This activity is intended for medical professionals in the field of oncology. Course Director Colin D. Weekes, MD, PhD
Massachusetts General Hospital Cancer Center
Speaker Max Diehn, MD, PhD
Stanford University ACCREDITATION In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 CreditTM Mass General Brigham designates this live activity for a maximum of 1Â AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Mass General Brigham designates this activity for 1 ANCC contact hour. Nurses should only claim credit commensurate with the extent of their participation in the activity. SMS Code for Attendance:
Text ### to 857-214-2277 This session will broadcast outside of Mass General Brigham The sessions in this series are being recorded<br>
slide2. Disclosure Summary of Relevant Financial Relationships MITIGATION STRATEGIES Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
Â
The following planners have reported no relevant financial relationship with an ineligible company:
Kellyann Jeffries, CNP
Â
The following planners have reported a relevant financial relationship with an ineligible company:
Colin D. Weekes, MD, PhD
Consultant: Ipsen, Genentech, Actuate Therapeutics
Research Funding: Novartis, Genentech, Actuate Therapeutics, Elicio Therapeutics, OncoC4, Deciphera Pharmaceuticals
Scientific Advisory Board: VRise Therapeutics
Kerry Reynolds
Advisory Board: SAGA Diagnostics Public Stock: Biogen (ended)
Priscilla Brastianos, MD
Consultant/Advisor: Kazia Clinical trial support: AstraZeneca, Eli Lily, Mirati, Merck, BMS, Kazia, Genentech Roche, Pfizer, GSK Institutional Research Support: Eli Lilly, Kinnate BioPharma, Mirati Therapeutics, Merck Consulting Fees: MPM, CraniUS, In Cephalo, Axiom
Â
The following speaker has reported a relevant financial relationship with an ineligible company:
Max Diehn, MD, PhD
Consultant: AstraZeneca, CiberMed, Gritstone Bio, Foresight Diagnostics, Regeneron
Research Funding: AstraZeneca
Honorarium: BMS
Founder: CiberMed, Foresight Diagnostics
Stock/Stock Options: CiberMed, Gritstone Bio, Foresight Diagnostics
Royalties/patent beneficiary: Celgene, Roche
Board Member: Foresight Diagnostics
Travel Support: Foresight Diagnostics, Regeneron<br>
Circulating Tumor DNA Analysis for Non-Invasive Detection of Cancers
May 9, 2024 | 12:00-1:00 PM Learning Objectives Upon completion of this activity, participants will be able to:
Evaluate recent advances or controversies in hematology/oncology treatment, clinical research and/or basic science investigation presented in this series
Assess opportunities to integrate information, tools or practices presented in this conference into how you deliver or support research and patient care
Incorporate new information or perspectives from this conference into specific aspects of your responsibilities in patient care, research or the system in which you work
Recognize evolving landscape of cancer care worldwide
Demonstrate the role of team science in the advancement of hematology/oncology treatment, clinical research and/or basic science investigation presented in this series
Target Audience This activity is intended for medical professionals in the field of oncology. Course Director Colin D. Weekes, MD, PhD
Massachusetts General Hospital Cancer Center
Speaker Max Diehn, MD, PhD
Stanford University ACCREDITATION In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 CreditTM Mass General Brigham designates this live activity for a maximum of 1Â AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Mass General Brigham designates this activity for 1 ANCC contact hour. Nurses should only claim credit commensurate with the extent of their participation in the activity. SMS Code for Attendance:
Text ### to 857-214-2277 This session will broadcast outside of Mass General Brigham The sessions in this series are being recorded<br>
slide2. Disclosure Summary of Relevant Financial Relationships MITIGATION STRATEGIES Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
Â
The following planners have reported no relevant financial relationship with an ineligible company:
Kellyann Jeffries, CNP
Â
The following planners have reported a relevant financial relationship with an ineligible company:
Colin D. Weekes, MD, PhD
Consultant: Ipsen, Genentech, Actuate Therapeutics
Research Funding: Novartis, Genentech, Actuate Therapeutics, Elicio Therapeutics, OncoC4, Deciphera Pharmaceuticals
Scientific Advisory Board: VRise Therapeutics
Kerry Reynolds
Advisory Board: SAGA Diagnostics Public Stock: Biogen (ended)
Priscilla Brastianos, MD
Consultant/Advisor: Kazia Clinical trial support: AstraZeneca, Eli Lily, Mirati, Merck, BMS, Kazia, Genentech Roche, Pfizer, GSK Institutional Research Support: Eli Lilly, Kinnate BioPharma, Mirati Therapeutics, Merck Consulting Fees: MPM, CraniUS, In Cephalo, Axiom
Â
The following speaker has reported a relevant financial relationship with an ineligible company:
Max Diehn, MD, PhD
Consultant: AstraZeneca, CiberMed, Gritstone Bio, Foresight Diagnostics, Regeneron
Research Funding: AstraZeneca
Honorarium: BMS
Founder: CiberMed, Foresight Diagnostics
Stock/Stock Options: CiberMed, Gritstone Bio, Foresight Diagnostics
Royalties/patent beneficiary: Celgene, Roche
Board Member: Foresight Diagnostics
Travel Support: Foresight Diagnostics, Regeneron<br>